This is a placebo-controlled, double blind, randomized, Phase II dose escalation study
intended to evaluate the potential safety and efficacy of tenecteplase for the treatment of
COVID-19 associated respiratory failure. The hypothesis is that administration of the drug,
in conjunction with heparin anticoagulation, will improve patients' clinical outcomes.